| 31.07 08:45 | dpa-AFX: Takeda Q1 Profit Increases; Backs FY Outlook |
| 31.07 08:20 | dpa-AFX: *TAKEDA EXPECTS FY24 EPS OF 37 YEN, CORE EPS OF 431 YEN |
| 31.07 08:20 | dpa-AFX: *TAKEDA Q1 CORE OPERATING PROFIT 382.3 BLN YEN VS. 326.3 BLN YEN LAST YEAR |
| 31.07 08:20 | dpa-AFX: *TAKEDA EXPECTS FY24 REVENUE OF 4.350 TRLN YEN |
| 31.07 08:19 | dpa-AFX: *TAKEDA Q1 CORE EPS 176 YEN VS. 150 YEN LAST YEAR |
| 31.07 08:19 | dpa-AFX: *TAKEDA Q1 NET INCOME 95.2 BLN YEN VS. 89.4 BLN YEN LAST YEAR |
| 31.07 08:19 | dpa-AFX: *TAKEDA Q1 OPERATING PROFIT 166.3 BLN YEN VS. 168.6 BLN YEN LAST YEAR |
| 31.07 08:19 | dpa-AFX: *TAKEDA Q1 REVENUE 1.208 TRLN YEN VS. 1.058 TRLN YEN LAST YEAR |
| 31.07 08:13 | dpa-AFX: *TAKEDA Q1 EPS 61 YEN VS 58 YEN LAST YEAR |
| 24.06 09:12 | dpa-AFX: Takeda Announces Approval Of LIVTENCITY In Japan |
| 24.06 09:04 | dpa-AFX: *TAKEDA GETS APPROVAL FOR LIVTENCITY IN JAPAN FOR REFRACTORY POST-TRANSPLANT CMV INFECTION/DISEASE |
| 21.06 14:56 | dpa-AFX: Health Canada Approves Takeda's HyQvia For Immunodeficiencies In Pediatric Patients |
| 21.06 14:05 | dpa-AFX: *TAKEDA CANADA GETS APPROVAL FOR HYQVIA AS PRIMARY & SECONDARY IMMUNODEFICIENCY REPLACEMENT THERAPY IN PEDIATRIC PATIENTS |
| 18.06 15:17 | dpa-AFX: Takeda Presents Long-Term Data From Phase 3 ADVANCE-CIDP 3 Trial Of HYQVIA In CIDP Patients |
| 18.06 14:06 | dpa-AFX: *TAKEDA REPORTS POSITIVE LONG-TERM RESULTS FOR HYQVIA IN CIDP MAINTENANCE TREATMENT |
| 17.06 15:29 | dpa-AFX: *OVID THERAPEUTICS REPORTS ON TAKEDA'S ANNOUNCEMENT OF PHASE 3 NEGATIVE RESULTS FOR SOTICLESTAT |
| 14.06 14:43 | dpa-AFX: Takeda Signs Option Agreement With Ascentage For Exclusive License For Olverembatinib |
| 14.06 14:06 | dpa-AFX: *TAKEDA SECURES EXCLUSIVE GLOBAL LICENSE OPTION FOR OLVEREMBATINIB FROM ASCENTAGE PHARMA |
| 07.06 05:12 | dpa-AFX: Former Takeda Employee Pleads Guilty To $2.3 Mln Embezzlement Scheme |
| 31.05 18:58 | dpa-AFX: Takeda Gets Positive CHMP Feedback For Recombinant ADAMTS13 |
|
|
